Cell News and Research

RSS

Zyomyx issued five new biotech patents

Zyomyx a privately held biotechnology company, has announced that the United States Patent and Trademark Office issued five new patents to the Company. With these additions, Zyomyx has further strengthened its proprietary position in the area of protein biochip technology development and commercialization.

6 Aug 2004

Lack of a gene called LBP-1a in the embryo prevents normal growth of blood vessels in the placenta

The lack of a gene called LBP-1a in the mouse embryo prevents normal growth of blood vessels in the placenta. This finding suggests that a similar defect in humans could play a role in fetal growth retardation, infant mortality and spontaneous abortion.

6 Aug 2004

Automated science speeds solution of Human Genome data

Scientists in Argonne's Biosciences Division are automating and accelerating the complex processes that coax a protein to reveal its structure so they can learn the role Nature assigned it.

6 Aug 2004

New fluorescent dye technique may provide new insight into how cancerous tumors begin and grow

A technique developed by University of California, San Diego biologists, which uses bright fluorescent dyes to reveal the activity of genes in individual cells of an organism, promises to be a boon to developmental biologists, and may provide new insight into how cancerous tumors begin and grow.

6 Aug 2004

New twist to the 2001 anthrax attacks in the U.S.

In a new twist to the 2001 anthrax attacks in the U.S., the Federal Bureau of Investigation is searching 2 homes in new York and New Jersey which may be related to the attacks.

5 Aug 2004

Second case of variant Creutzfeldt-Jakob disease infection that was probably caused by blood transfusion

Research reported in The Lancet this week details the second case of variant Creutzfeldt-Jakob disease (vCJD) infection that was probably caused by blood transfusion. The rogue prion responsible for vCJD was identified at postmortem five years after an elderly person received a blood transfusion from a donor who later developed vCJD.

5 Aug 2004

Promising new cancer drug, Nanotax

A Lawrence company that uses patented technology created at the University of Kansas to improve the effectiveness of drugs has won a $100,000 National Institutes of Health grant to support further testing of the company's promising new cancer drug, Nanotax.

5 Aug 2004

Physicians offer several promising and unique approaches to brain tumor treatment

An estimated 41,000 new cases of primary brain tumors are expected to be diagnosed in 2004, according to the American Brain Tumor Association.

5 Aug 2004

First evidence of the molecular link between inflammation and cancer

The investigators found that a gene called I-kappa-B kinase (IKK beta), a pro-inflammatory gene, acts differently in two cell types to cause cancer. When IKK beta was deleted, the cancer incidence and tumor growth in mice was decreased by nearly 80 percent.

5 Aug 2004

New gene-silencing technique

A new gene-silencing technique that takes place in the nucleus of human cells, has been demonstrated by researchers at the University of California, San Diego (UCSD) School of Medicine and the VA San Diego Healthcare System.

5 Aug 2004

Experimental vaccine against ricin

Scientists have developed an experimental vaccine against ricin, a potential biological threat agent, which fully protected mice from aerosol challenge with lethal doses of the toxin.

5 Aug 2004

Protein loss plays role in acute T-cell leukemia

The loss of a key protein (Smad3) in a pathway that helps prevent tumors from forming is specific to one form of childhood leukemia, but not to other pediatric and adult forms of leukemia, according to a new study published in the August 5, 2004, New England Journal of Medicine.

5 Aug 2004

New screening test for oesophageal (food pipe) cancer

A new screening test for oesophageal (food pipe) cancer could dramatically improve survival from the disease, according to research published in the British Journal of Cancer this week.

5 Aug 2004

Smart drug that targets cancer cells in the brain following removal of a tumor

The use of a "smart" drug that targets cancer cells in the brain following removal of a tumor may provide treatment that can extend the survival of people with the most common form of primary malignant brain tumor, glioblastoma multiforme (GBM).

3 Aug 2004

Successfully cloning mice from an advanced melanoma cell

Nature can reset the clock in certain types of cancer and reverse many of the elements responsible for causing malignancy, reports a research team led by Whitehead Institute Member Rudolf Jaenisch, in collaboration with Lynda Chin from Dana Farber Cancer Institute.

3 Aug 2004